TITLE

Is There Clear and Convincing Evidence of Cardiovascular Risk with Rosiglitazone?

AUTHOR(S)
Kaul, S.; Diamond, G. A.
PUB. DATE
June 2011
SOURCE
Clinical Pharmacology & Therapeutics;Jun2011, Vol. 89 Issue 6, p773
SOURCE TYPE
Academic Journal
DOC. TYPE
Opinion
ABSTRACT
In this article, the author focuses on the cardiovascular safety of rosiglitazone, a thiazolidinedione drug designed for glycemic control among type 2 diabetics. The author states that meta-analyses conducted by the U.S. Food and Drug Administration (FDA) shows the association of rosiglitazone with myocardial infarction and increased risk of ischemic events. The author says that physicians may be free to weigh the risks and benefits of rosiglitazone until evidence of harmful effects is clear.
ACCESSION #
60677490

 

Related Articles

  • META-ANALYSIS OF "SPARSE" DATA: PERSPECTIVES FROM THE AVANDIA CASES. Finkelstein, Michael O.; Levin, Bruce // Jurimetrics: The Journal of Law, Science & Technology;Winter2012, Vol. 52 Issue 2, p123 

    Combining the results of multiple small trials to increase accuracy and statistical power, a technique called meta-analysis has become well established and increasingly important in medical studies, particularly in connection with new drugs. When the data are sparse, as they are in many such...

  • US safety alert over rosiglitazone.  // Pulse;5/24/2007, Vol. 67 Issue 20, p4 

    The article focuses on the issuance of the U.S. Food and Drug Administration's safety alert over glitazone. This is due to the meta-analysis suggesting that glitazone increased cardiovascular risks. Research found out that rosiglitazone raised the risk of myocardial infarction by 43 percent and...

  • FDA Panel: Keep Avandia on Market With Restrictions.  // Bioworld Week;7/19/2010, Vol. 18 Issue 29, p1 

    The article reports on the restrictions made by the panel of the U.S. Food and Drug Administration regarding the type II diabetes drug Avandia (rosiglitazone) from GlaxoSmithKline. It mentions the availability of the drug in the U.S. market despite the warnings and limited use related to heart...

  • Is your patient still using rosiglitazone? Gov-Ari, Hanna K.; Stevermer, James J. // Clinician Reviews;Aug2011, Vol. 21 Issue 8, p30 

    The article reports that doctors have stopped prescribing rosiglitazone when a study linked it to an elevated myocardial infarction (MI) risk. That it is not advised to switch to pioglitazone instead of initiating rosiglitazone therapy for patients with diabetes is pointed out. Although removing...

  • Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. Caldwell, Brent; Aldington, Sarah; Weatherall, Mark; Shirtcliffe, Philippa; Beasley, Richard // Journal of the Royal Society of Medicine;Mar2006, Vol. 99 Issue 3, p132 

    Objectives: To examine whether the increased risk of cardiovascular events with rofecoxib represents a class effect of cyclooxygenase-2 (COX-2) specific inhibitors. Design: Systematic review and meta-analysis of randomized double-blind clinical trials of celecoxib of at least 6 weeks' duration...

  • Study links diabetes drug to heart deaths. Tanne, Janice Hopkins // BMJ: British Medical Journal (International Edition);5/26/2007, Vol. 334 Issue 7603, p1073 

    This article reports on the findings of a meta-analysis of 42 trials on the use of the drug Avandia which was published in the "New England Journal of Medicine." The analysis found that the diabetes drug rosiglitazone has shown an increased risk of myocardial infarction and an increase in...

  • FDA eliminating REMS for rosiglitazone.  // Reactions Weekly;1/9/2016, Vol. 1583 Issue 1, p8 

    The article reports that the U.S. Food and Drug Administration (FDA) is eliminating the Risk Evaluation and Mitigation Strategy (REMS) for rosiglitazone products as the benefits of the drug outweigh the risks, and removal of rosiglitazone does not increase the risk of myocardial infarction.

  • FDA considers data confidentiality for diabetes drugs. Traynor, Kate // American Journal of Health-System Pharmacy;10/1/2014, Vol. 71 Issue 19, p1607 

    The article reports that the U.S. Food and Drug Administration (FDA) is considering whether to release information related to the cardiovascular risks for diabetes drugs that have been detected in interim clinical trials. Topics covered include the plan to receive feedback about the proper way...

  • The need for regulatory science.  // Nature Reviews Drug Discovery;Aug2010, Vol. 9 Issue 8, p577 

    The quandary faced by regulators in deciding the fate of the controversial diabetes drug rosiglitazone (Avandia; GlaxoSmithKline) illustrates the importance of investment and innovation in the field of regulatory science.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics